# Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

> **NCT07346807** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 69 (estimated)

## Conditions studied

- Tongue Squamous Cell Carcinoma

## Interventions

- **PROCEDURE:** Lingual Nerve Disruption
- **DRUG:** Tislelizumab
- **DRUG:** Albumin-bound Paclitaxel
- **PROCEDURE:** Cisplatin
- **PROCEDURE:** Peripheral Blood Collection for Immune Monitoring
- **OTHER:** Pain and Quality of Life Assessment

## Key facts

- **NCT ID:** NCT07346807
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07346807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07346807, "Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07346807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*